Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Ann Thorac Surg. 2019 Aug;108(2):474-480. doi: 10.1016/j.athoracsur.2019.02.064. Epub 2019 May 2.
This study focused on contemporary outcomes after coronary artery bypass graft (CABG) surgery versus percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (MVCAD).
This was a propensity-matched retrospective, observational analysis. Patients with MVCAD who underwent CABG or PCI between 2010 and 2018 and for whom data were available through the National Cardiovascular Data Registry or The Society of Thoracic Surgeons Adult Cardiac Surgery Database were included. The primary outcome was overall survival. Secondary outcomes included freedom from inpatient readmission and freedom from repeat revascularization.
Of the initial 6,163 patients with MVCAD, the propensity-matched cohort included 844 in each group. The estimated 1-year mortality was 11.5% and 7.2% (p < 0.001) in the PCI and CABG groups, respectively, with an overall hazard ratio for mortality of PCI versus CABG of 1.64 (95% confidence interval [CI], 1.29 to 2.10; p < 0.001). The overall hazard ratio for readmission for PCI versus CABG was 1.42 (95% CI, 1.23 to 1.64; p < 0.001). The overall hazard ratio for repeat revascularization for PCI versus CABG was 4.06 (95% CI, 2.39 to 6.91; p < 0.001). Overall major adverse cardiovascular events and individual outcomes of mortality, readmission, and repeat revascularization all favored CABG across virtually all major clinical subgroups.
This contemporary propensity-matched analysis of patients undergoing coronary revascularization for MVCAD demonstrates a significant mortality benefit with CABG over PCI, and this benefit is consistent across virtually all major patient subgroups. Futures studies are needed reflecting routine practice to assess how best to approach shared decision making and informed consent when it comes to revascularization decisions in any patient with MVCAD.
本研究聚焦于多支血管冠状动脉疾病(MVCAD)患者行冠状动脉旁路移植术(CABG)与经皮冠状动脉介入治疗(PCI)的当代结局。
这是一项倾向匹配的回顾性观察性分析。纳入 2010 年至 2018 年间接受 CABG 或 PCI 治疗且国家心血管数据注册中心或胸外科医师学会成人心脏外科学数据库中存在相关数据的 MVCAD 患者。主要结局为总体生存率。次要结局包括无住院再入院率和无重复血运重建率。
在最初的 6163 例 MVCAD 患者中,倾向匹配队列中每组各有 844 例患者。PCI 组和 CABG 组的 1 年死亡率分别为 11.5%和 7.2%(p<0.001),PCI 与 CABG 的死亡率总体风险比为 1.64(95%置信区间,1.29 至 2.10;p<0.001)。PCI 与 CABG 的再入院总体风险比为 1.42(95%置信区间,1.23 至 1.64;p<0.001)。PCI 与 CABG 的重复血运重建总体风险比为 4.06(95%置信区间,2.39 至 6.91;p<0.001)。在几乎所有主要临床亚组中,CABG 在总体主要不良心血管事件和死亡率、再入院率及重复血运重建率等各单个结局上均优于 PCI。
本项针对 MVCAD 患者行冠状动脉血运重建的当代倾向匹配分析表明,CABG 相较于 PCI 具有显著的死亡率获益,且该获益在几乎所有主要患者亚组中一致。未来需要进行反映常规实践的研究,以评估在任何 MVCAD 患者中进行血运重建决策时,如何最好地开展共同决策和知情同意。